Stablepharma and a World Leader in Sterile Manufacturing Announce Partnership to Manufacture the first Fridge-Free Tetanus diphtheria (Td) Vaccine

June 15th, 2022

London, UK – Stablepharma Ltd., a UK-based biotechnology company pioneering fridge-free vaccines today announced a collaboration agreement with a world leader in sterile manufacturing and serving science, to manufacture thermostable Tetanus diphtheria (Td) vaccines at their facilities in Italy.

“Our new partner is one of the world’s leading sterile manufacturing companies, offering a full range of products and services that will enable Stablepharma to deliver innovative fridge-free Tetanus diphtheria (Td) vaccines to patients, no matter where they are in the world,” said Özgür Tuncer, CEO & Executive Director of Stablepharma, the Fridge-Free Vaccine Company. “We are very pleased to have signed a collaboration agreement as a long-term manufacturing partner that will enable us to focus on moving our StablevaX™ technology forward”.

This partnership will support Stablepharma through clinical development of the StablevaX™-Td product, as well as the capability to scale-up and establishing commercial scale sterile manufacturing. “Through this new collaboration agreement, we look forward to working with the Stablepharma R&D team to bring a thermostable Td vaccine to patients around the world”, said a member of the Partnership Team.

“This is a pivotal time for Stablepharma as we progress the development and manufacture of our first fridge-free vaccine StablevaX™-Td”, added Özgür. “By eliminating the need for the cold-chain, fridge-free vaccines could result in health economic savings of up to $100 per patient in low income countries – this in itself is a huge incentive for us to progress our technology with our partners”.

About Stablepharma Ltd

Stablepharma Ltd, the Fridge-Free Vaccine Company, is an innovative biotech company developing a range of next generation fridge-free vaccine products. Stablepharma was founded with a simple purpose; to use its novel technology to dramatically improve health outcomes for those adults and children most at risk of death and disability caused by vaccine preventable diseases.  www.stablepharma.com.

MENU